

FAQs About Cell and Gene Access Model

Created: 12/10/2025

Revised: 12/30/2025



The Wisconsin Department of Health Services (DHS) began participating on January 1, 2026, in the Centers for Medicare & Medicaid Services Cell and Gene Therapy (CGT) Access Model.

ForwardHealth has developed this FAQs document to capture questions about this program and share answers. This document will be revised with new information as it is available.

Question: What is the CGT Access Model?

Answer: The CGT Access Model is a federal program that allowed DHS to enter into enhanced rebate agreements with the manufacturers of two State-Selected Model Drugs, Casgevy and Lyfgenia, which will provide treatments within a framework that lowers the prices of these drugs and ties payments to health outcomes through improving access to CGTs. The model's initial focus is for people living with sickle cell disease (SCD).

Question: Casgevy is also used to treat β -thalassemia. Is this included in the CGT Access Model?

Answer: No, Casgevy used to treat β -thalassemia is **not** included in the CGT Access Model at this time.

Question: Who can participate in the CGT Access Model?

Answer: BadgerCare Plus and Medicaid members may qualify to participate, but the model does not apply to members enrolled in the separate Children's Health Insurance Program portion of BadgerCare Plus.

To qualify, members must:

- Have a documented medical diagnosis of SCD.
- Have Wisconsin Medicaid as the primary payer for a State-Selected Model Drug.
- Have received an infusion of a State-Selected Model Drug.
- Have received that infusion while the CGT Access Model outcome-based agreements between DHS and the drug manufacturers are in effect.

Question: Is fertility preservation available?

Answer: Yes. Fertility preservation is **only** available to members who are participating in the CGT Access Model, but it is **not** a covered BadgerCare Plus or Medicaid benefit. Fertility preservation is only offered through the manufacturers of Casgevy and Lyfgenia. Members with SCD who are not participating in the model cannot receive these services. Providers should follow the drug manufacturers' guidance about referrals for fertility preservation.

Question: Will participation in the CGT Access Model affect a member's HMO enrollment?

Answer: Yes, members who participate in the CGT Access Model will be permanently exempted from HMO enrollment once an infusion date has been scheduled, beginning on the first of the month of the first round of apheresis. This exemption can be requested by the member or the HMO, and appropriate documentation showing an approved prior authorization and scheduled infusion date must accompany the request. For more information, refer to ForwardHealth Online Handbook Disenrollment and Exemptions topic [#392](#).

FAQs About Cell and Gene Access Model

Created: 12/10/2025

Revised: 12/30/2025



Question: Can Medicaid members who have SCD get help with rides to their health care appointments?

Answer: Yes. Non-emergency medical transportation (NEMT) can provide members with free transportation options if they have no other way to get to a medical appointment. Transportation to any SCD-related appointments is considered a **critical care ride**, which means:

- It can be scheduled before or on the same day as the appointment.
- Members can get additional support from NEMT call center representatives.

Members should indicate that the ride is related to SCD at the time of scheduling. Refer to the [Medicaid: Non-Emergency Medical Transportation](#) page on the DHS website for more information and instructions on scheduling rides.

Question: How can my clinic or facility be certified as a qualified treatment center?

Answer: In order to administer Casgevy or Lyfgenia, providers need to be certified with the drug's manufacturer. Providers can contact [Genetix Biotherapeutics](#) or [Vertex Pharmaceuticals](#) for more information.

Question: Will there be any additional billing changes to clinical services?

Answer: No, there are no additional billing changes to clinical services. Clinical services associated with the administration of Casgevy or Lyfgenia will be reimbursed according to current policy. Refer to the [Online Handbook](#) for details.

Question: Will Casgevy and Lyfgenia remain on the Select High Cost, Orphan, and Accelerated Approval Drugs data table?

Answer: Yes, they will continue to be listed on the [Select High Cost, Orphan, and Accelerated Approval Drugs](#) data table. For information about reimbursement for drugs covered under the pharmacy benefit, providers may refer to the Covered Outpatient Drug Reimbursement topic [#1351](#).

For specific questions about the billing or coverage of high cost, orphan, and accelerated approval drugs, providers may:

- Contact Provider Services at 800-947-9627, Monday–Friday, 8 a.m.–6 p.m., Central Time.
- Email DHSOrphanDrugs@dhs.wisconsin.gov

For more information on Casgevy, refer to the Casgevy topic [#23658](#). For more information on Lyfgenia, refer to the Lyfgenia topic [#23657](#).

**FAQs About
Cell and Gene Access Model**

Created: 12/10/2025

Revised: 12/30/2025

